journal article·2018-03

Rodlike Supramolecular Nanoassemblies of Degradable Poly(Aspartic Acid) Derivatives and Hydroxyl‐Rich Polycations for Effective Delivery of Versatile Tumor‐Suppressive ncRNAs

Hai‐Qing Song, Wenting Pan, Rui‐Quan Li, Bingran Yu, Wenjuan Liu, Ming Yang, Fu‐Jian Xu

Small· Volume 14· Issue 9
Publisher page

Abstract

Abstract The delivery of tumor‐suppressive noncoding RNAs (ncRNAs) including short ncRNAs (i.e., miRNAs) and long ncRNAs (lncRNAs) is put forward to treat tumors. In this work, novel rodlike supramolecular nanoassemblies (CNC @CB[8] @ PGEA) of degradable poly(aspartic acid) (PAsp) derivatives‐grafted cellulose nanocrystals (CNCs) and hydroxyl‐rich polycations (ethanolamine‐functionalized poly(glycidyl methacrylate), PGEA) are proposed via typical cucurbit[8]uril (CB[8])‐based host–guest interactions for delivery of different ncRNAs to treat hepatocellular carcinoma (HCC). Spindly CNCs, one kind of natural polysaccharide nanoparticles, possess good biocompatibility and unique physico‐chemical properties. PGEA with abundant hydroxyl groups is one promising gene carrier with low cytotoxicity. PAsp can benefit the disassembly and degradability of nanoassemblies within cells. CNC @ CB[8]@PGEA combines the different unique properties of CNC, PGEA, and PAsp. CNC @ CB[8] @ PGEA effectively complexes the expression constructs of miR‐101 (plasmid pc3.0‐miR‐101) and lncRNA MEG3 (plasmid pc3.0‐MEG3). CNC @ CB[8] @ PGEA produces much better transfection performances than PGEA‐containing assembly units. In addition, the codelivery system of CNC @ CB[8] @ PGEA/(pc3.0‐MEG3+pc3.0‐miR‐101) nanocomplexes demonstrates better efficacy in suppressing HCC than CNC @ CB[8] @ PGEA/pc3.0‐MEG3 or CNC @ CB[8] @ PGEA/pc3.0‐miR‐101 nanocomplexes alone. Such rodlike supramolecular nanoassemblies will provide a promising means to produce efficient delivery vectors of versatile tumor‐suppressive nucleic acids.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Chemical Resource Engineering Beijing Laboratory of Biomedical Materials Beijing Advanced Innovation Center for Soft Matter Science and Engineering Beijing University of Chemical Technology 15 BeiSanhuan East Road Beijing 100029 China

Shandong Provincial Key Laboratory of Radiation Oncology Cancer Research Center Shandong Cancer Hospital Affiliated to Shandong University Shandong Academy of Medical Sciences 440 Jiyan Road Jinan 250117 Shangdong China

Funding

National Natural Science Foundation of China

References (47)

Show source-provided references
1. 10.3322/caac.2133210.3322/caac.21332 ↗
2. Jaleh V. · World J. Gastroenterol. · 2015 · 21 · 1202210.3748/wjg.v21.i42.12022 ↗
3. 10.1002/hep.2146710.1002/hep.21467 ↗
4. 10.1016/j.cell.2009.01.00210.1016/j.cell.2009.01.002 ↗
5. 10.1158/0008-5472.CAN-08-288610.1158/0008-5472.CAN-08-2886 ↗
6. 10.1172/JCI8442110.1172/JCI84421 ↗
7. 10.1002/adfm.20160304110.1002/adfm.201603041 ↗
8. 10.1158/0008-5472.CAN-09-388510.1158/0008-5472.CAN-09-3885 ↗
9. 10.1038/ncb178710.1038/ncb1787 ↗
10. 10.1002/hep.2567910.1002/hep.25679 ↗
11. Wang L. · Hepatology · 2014 · 59 · 850
12. 10.1016/j.jhep.2013.10.02810.1016/j.jhep.2013.10.028 ↗
13. Mondal T. · Nat. Commun. · 2015 · 26 · 774310.1038/ncomms8743 ↗
14. 10.1021/acs.biomac.6b0112010.1021/acs.biomac.6b01120 ↗
15. 10.1016/j.jconrel.2016.06.01410.1016/j.jconrel.2016.06.014 ↗
16. 10.1039/C5BM00530B10.1039/C5BM00530B ↗
17. 10.1126/sciadv.160010210.1126/sciadv.1600102 ↗
18. 10.1002/ange.20170554310.1002/ange.201705543 ↗
19. 10.1002/adfm.20160622910.1002/adfm.201606229 ↗
20. 10.1002/adma.20140081510.1002/adma.201400815 ↗
21. 10.1016/j.jconrel.2015.02.01810.1016/j.jconrel.2015.02.018 ↗
22. 10.1073/pnas.080176310510.1073/pnas.0801763105 ↗
23. 10.1016/j.biomaterials.2009.09.06010.1016/j.biomaterials.2009.09.060 ↗
24. 10.1021/cr900339w10.1021/cr900339w ↗
25. 10.1021/ja304456810.1021/ja3044568 ↗
26. 10.1021/acsami.5b0243210.1021/acsami.5b02432 ↗
27. 10.1021/bm301955k10.1021/bm301955k ↗
28. 10.1021/bm401593n10.1021/bm401593n ↗
29. 10.1021/bm060620d10.1021/bm060620d ↗
30. 10.1021/nn901213a10.1021/nn901213a ↗
31. 10.1039/c1cc10934k10.1039/c1cc10934k ↗
32. 10.1021/bc400115e10.1021/bc400115e ↗
33. 10.1021/acs.accounts.6b0047710.1021/acs.accounts.6b00477 ↗
34. 10.1021/ja106362w10.1021/ja106362w ↗
35. 10.1002/adma.20090129110.1002/adma.200901291 ↗
36. 10.1002/adma.20160231910.1002/adma.201602319 ↗
37. 10.1016/j.biomaterials.2016.11.05510.1016/j.biomaterials.2016.11.055 ↗
38. 10.1002/adfm.20170125510.1002/adfm.201701255 ↗
39. 10.1039/C4NR07515C10.1039/C4NR07515C ↗
40. 10.1074/jbc.M70202920010.1074/jbc.M702029200 ↗
41. 10.1021/acsnano.6b0323810.1021/acsnano.6b03238 ↗
42. 10.1038/nature1861010.1038/nature18610 ↗
43. 10.1021/la201588s10.1021/la201588s ↗
44. 10.1021/ol025869w10.1021/ol025869w ↗
45. 10.1016/j.biomaterials.2016.08.02510.1016/j.biomaterials.2016.08.025 ↗
46. 10.1093/hmg/ddw05610.1093/hmg/ddw056 ↗
47. 10.18632/oncotarget.674710.18632/oncotarget.6747 ↗